Manages nasal symptoms of perennial nonallergic rhinitis. ANDA 77538, held by Apotex. Fluticasone Propionate.
As of Nov 16, 2026, ANDA 77538 (Fluticasone Propionate), held by Apotex, was first approved by FDA on Sep 12, 2007, with 3 approved supplements and 0 published complete response letters.
Fluticasone propionate nasal spray, USP is indicated for the management of the nasal symptoms of perennial nonallergic rhinitis in adult and pediatric patients aged 4 years and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 12, 2007 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluticasone Propionate0.05MG/SPRAY · spray, metered;nasal | Fluticasone Propionate | Rx |
| Aug 13, 2020 | Supplement 31Labeling · Standard review | Approved | None posted |
| Apr 18, 2017 | Supplement 19Manufacturing | Approved | None posted |
| Apr 18, 2017 | Supplement 15Labeling · Standard review | Approved | None posted |
| Sep 12, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters